For mothers living with epilepsy, the decision to start or continue medication during pregnancy is often fraught with anxiety. The potential for antiepileptic drugs (AEDs) to impact fetal development is a serious concern, but abruptly stopping medication can also pose significant risks to the mother’s health. Now, a breakthrough offers a glimmer of hope: scientists are developing a genetic test that could aid predict how a fetus will respond to these vital medications, potentially allowing for safer, more informed treatment decisions.
The challenge lies in the complex way AEDs can affect a developing baby. While most children born to mothers with epilepsy are healthy, there is an increased risk of birth defects. However, stopping medication due to these fears can lead to uncontrolled seizures, which are also dangerous for both mother and child. Finding the right balance – ensuring the mother’s health while minimizing potential risks to the fetus – has long been a delicate act. This new research, highlighted by Monash University, aims to move beyond a one-size-fits-all approach and toward personalized medicine for pregnant women with epilepsy. Monash University reported on the development of this genetic test in February 2026.
Understanding the Risks and the Necessitate for Precision
Epilepsy affects approximately 1% of all pregnancies, making this a significant public health issue. As detailed in a 2012 study published in the Journal of Research in Medical Sciences, antiepileptic drugs have the potential to interfere with fetal development throughout pregnancy. The study, authored by Leila Etemad, Mohammad Moshiri and Seyed Adel Moallem, emphasizes that while AEDs can pose risks, pregnant women should not discontinue their medication without medical guidance.
The specific risks associated with AEDs vary depending on the drug, the dosage, and individual genetic factors. Some AEDs have been linked to a higher incidence of certain birth defects, such as neural tube defects, cleft palate, and congenital heart defects. However, the absolute risk remains relatively low, and many women taking AEDs deliver healthy babies. The key is to carefully weigh the benefits of seizure control against the potential risks to the fetus, a process that is currently based on general guidelines and clinical judgment.
How the Genetic Test Could Work
The genetic test under development focuses on identifying variations in genes that influence how the body processes AEDs. These variations can affect the levels of the drug in the mother’s bloodstream and, the amount of the drug that reaches the fetus. By analyzing a mother’s genetic profile, doctors could potentially predict how she will metabolize a particular AED and adjust the dosage accordingly, minimizing the risk of adverse effects on the baby.
Researchers are also investigating genes that may influence the fetus’s susceptibility to the effects of AEDs. Some fetuses may be more vulnerable to the teratogenic effects of these drugs due to genetic predispositions. Identifying these vulnerabilities could allow doctors to choose alternative medications or implement closer monitoring during pregnancy.
The Path Forward and Remaining Questions
While the genetic test is still in development, the initial results are promising. Scientists are currently conducting clinical trials to validate the test’s accuracy and reliability. If successful, the test could become a standard part of prenatal care for women with epilepsy, empowering them to craft more informed decisions about their treatment. The goal is to provide a personalized approach to managing epilepsy during pregnancy, maximizing the chances of a healthy outcome for both mother and child.
However, several questions remain. The genetic test is unlikely to provide a definitive answer in every case. Other factors, such as maternal health, lifestyle, and environmental exposures, can also influence fetal development. The test may not be able to predict all possible birth defects. It’s crucial to remember that the test is a tool to aid in decision-making, not a guarantee of a perfect outcome.
The development of this genetic test represents a significant step forward in the care of pregnant women with epilepsy. It reflects a growing trend toward personalized medicine, where treatment decisions are tailored to the individual characteristics of each patient. As research continues and our understanding of the complex interplay between genetics, medications, and fetal development deepens, we can expect even more innovative approaches to managing epilepsy during pregnancy.
Disclaimer: This article provides general information about epilepsy and pregnancy and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
The next update on the clinical trials for this genetic test is expected in late 2026, as researchers continue to gather data and refine the test’s accuracy. If you or someone you know is affected by epilepsy, please reach out to the Epilepsy Foundation for support and resources. Share this article with anyone who might find it helpful.
